..for the newsletter?
Phosphagenics will convene a medical advisory panel as soon as possible to prioritise
the pain indication it will pursue first for the TPM/oxycodone patch. Once the indication
has been selected, the Company will seek ethics approval for a Phase 2 clinical trial, to
establish efficacy of the patch in providing relief from pain. Phosphagenics believes that
the unique drug delivery properties of TPM® will provide it with the opportunity to develop
the first opioid product to be approved for treatment of a neuropathic pain indication.
salmon fishing, page-12
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.338M | |||
| Open | High | Low | Value | Volume |
| 0.2¢ | 0.2¢ | 0.2¢ | $1.334K | 667.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 23 | 24225503 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 34738413 | 20 |
View Market Depth
| Last trade - 15.01pm 15/10/2024 (20 minute delay) ? |
| AVE (ASX) Chart |